• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Crispr Therapeutics Ag (NQ: CRSP )

    46.74 -1.44 (-2.99%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 23, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 955,257
    Open 48.54
    Bid (Size) 46.73 (1)
    Ask (Size) 47.57 (1)
    Prev. Close 48.18
    Today's Range 46.73 - 48.56
    52wk Range 37.55 - 91.10
    Shares Outstanding 78,935,098
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    3 Dirt Cheap Stocks to Buy Right Now
    Bargain hunters should love these great stocks. 
    Via The Motley Fool
    Down 21% This Year, Is CRISPR Therapeutics Stock Still a Buy?
    There's a lot of growth on the way, and soon. 
    Via The Motley Fool

    Performance

    YTD
    -29.25%
    -29.25%
    1 Month
    -4.94%
    -4.94%
    3 Month
    -19.33%
    -19.33%
    6 Month
    -34.24%
    -34.24%
    1 Year
    +1.92%
    +1.92%

    More News

    Read More
    1 Biotech Stock Down 62% to Buy and Hold
    Via The Motley Fool
    3 No-Brainer Biotech Stocks to Buy With $200 Right Now
    Via The Motley Fool
    Looking for Stock Bargains With Room to Run? Try This.
    Via The Motley Fool
    Down Nearly 50% From Its 52-Week High, Is CRISPR Therapeutics a Steal of a Deal?
    Via The Motley Fool
    3 Monster Biotech Stocks to Buy Before 2025
    Via The Motley Fool
    Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
    Via The Motley Fool
    Got the Market Sell-Off Blues? Do These 3 Things Right Now
    Via The Motley Fool
    Jim Cramer: This Energy Stock Is A Buy, Stay Away From DexCom
    Via Benzinga
    7 Biotech Stocks to Buy for Their Game-Changing Potential
    Via InvestorPlace
    The 3 Best Gene Editing Stocks to Buy in August 2024
    Via InvestorPlace
    Is It Too Late to Buy Vertex Pharmaceuticals Stock?
    Via The Motley Fool
    CRSP Stock Earnings: CRISPR Therapeutics Beats EPS, Misses Revenue for Q2 2024
    Via InvestorPlace
    Prediction: These Could Be the Best-Performing Growth Stocks Through 2030
    Via The Motley Fool
    Prediction: CRISPR Therapeutics Stock Could Be a Millionaire-Maker
    Via The Motley Fool
    3 Unstoppable Stocks to Buy in August
    Via The Motley Fool
    10 Best Small and Mid-Cap Stocks to Consider Buying in August
    Via The Motley Fool
    Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
    Via The Motley Fool
    The Top 3 Cathie Wood Stocks to Buy Now: Summer 2024
    Via InvestorPlace
    3 Small-Cap Stocks to Buy at a 52-Week Low
    Via InvestorPlace
    3 Gene Editing Stocks Shaping the Future of Medicine
    Via InvestorPlace
    3 Monster Stocks in the Making to Buy Right Now
    Via The Motley Fool
    3 Gene Editing Stocks That Could Grow Your Wealth
    Via InvestorPlace
    3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition
    Via InvestorPlace
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.